ArticleInvestigative and clinical urology2025
Induction of apoptosis and growth inhibition by silodosin and abiraterone acetate in PC-3 human prostate cancer cells.
Article in Investigative and clinical urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Therapeutic potentials of curcumin in prostate cancer: a comprehensive review of pathways and clinical prospects.Prostate international · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeProstate cancer that progresses despite androgen deprivation therapy, known as metastatic castration-resistant prostate cancer (mCRPC) is notoriously difficult to treat. While abiraterone acetate (AA) is a standard therapy, repurposing drugs like silodosin, a selective α1A-adrenoceptor antagonist, offers promising potential. MATERIALS AND
methodsPC-3 human prostate cancer cells were treated with silodosin, AA, or their combination. Cell viability was assessed via CCK-8 assay, apoptosis by Annexin V-FITC/PI flow cytometry, and drug interaction using CompuSyn to determine combination index (CI) and dose reduction index (DRI).
resultsBoth silodosin and AA reduced cell viability concentration-dependently (half-maximal inhibitory concentration [IC₅₀]: 44.16 mM and 66.90 µM, respectively). Combination therapy yielded the lowest viability (18.03%±5.73%), significantly outperforming AA (41.79%±13.11%) and silodosin (45.35%±11.51%) alone. Silodosin induced greater apoptosis (80.94%±15.88%) than AA (22.93%±7.41%), while the combination further enhanced apoptosis (87.41%±12.25%). At ¼ IC₅₀ doses, the combination retained efficacy using markedly reduced concentrations-16.72 µM AA (8-fold reduction) and 11.04 mM silodosin (5-fold reduction). CI values across fractional effects remained <1, confirming synergism, with favorable DRI values indicating enhanced efficacy at lower doses.
conclusionsSilodosin exhibits potent effects in reducing cell viability and promoting apoptosis in androgen-insensitive prostate cancer cells, comparable to AA. When combined, both agents demonstrate synergistic effects with reduced dosing requirements. These findings support further investigation of silodosin as a potential therapeutic in mCRPC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.